Literature DB >> 20143498

Minority participation in randomized controlled trials for obsessive-compulsive disorder.

Monnica Williams1, Mark Powers, Yeo-Gin Yun, Edna Foa.   

Abstract

This paper reviews published randomized trials in North America to determine whether minority groups are underrepresented in clinical trials of OCD. A search of the literature produced 40 randomized trials of both adults and children with OCD, conducted in the U.S. and Canada from 1989 to 2009 (N = 3777). The groups included in this review were Caucasians/European Americans, Black/African-Americans, Hispanic/Latino-Americans, Asian-Americans, Others, and Unknown. Of these, 22 of 40 trials reported ethnic/racial information or data was available by request. We focused on the 21 trials from 1995 to 2008 providing ethnic/racial information, and among those (N = 2221), 91.5% of participants were Caucasian, 1.3% were African-American, 1.0% were Hispanic, 1.6% were Asian, 1.5% were Other, and 3.1% were Unknown. We conclude that minorities are underrepresented in North American OCD trials. Therefore, it is not known if empirically validated treatments are effective for these groups. Recommendations for improving recruitment of minorities for future studies are discussed.

Entities:  

Mesh:

Year:  2010        PMID: 20143498      PMCID: PMC3431431          DOI: 10.1016/j.janxdis.2009.11.004

Source DB:  PubMed          Journal:  J Anxiety Disord        ISSN: 0887-6185


  61 in total

1.  Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.

Authors:  R Hoehn-Saric; P Ninan; D W Black; S Stahl; J H Greist; B Lydiard; S McElroy; J Zajecka; D Chapman; C Clary; W Harrison
Journal:  Arch Gen Psychiatry       Date:  2000-01

2.  A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine.

Authors:  Eriko Nakatani; Akiko Nakagawa; Tomohiro Nakao; Chika Yoshizato; Maiko Nabeyama; Akiko Kudo; Kayoko Isomura; Naoko Kato; Kazuko Yoshioka; Midori Kawamoto
Journal:  Psychother Psychosom       Date:  2005       Impact factor: 17.659

3.  OCD symptoms in a sample of Turkish patients: a phenomenological picture.

Authors:  Filiz Karadaĝ; Nalan Kalkan Oguzhanoglu; Osman Ozdel; Figen C Ateşci; Tarkan Amuk
Journal:  Depress Anxiety       Date:  2006       Impact factor: 6.505

4.  A legacy of distrust: African Americans and medical research.

Authors:  V N Gamble
Journal:  Am J Prev Med       Date:  1993 Nov-Dec       Impact factor: 5.043

5.  Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.

Authors:  S Romano; W Goodman; R Tamura; J Gonzales
Journal:  J Clin Psychopharmacol       Date:  2001-02       Impact factor: 3.153

6.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

7.  Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder.

Authors:  Lorrin M Koran; Elizabeth Hackett; Arkady Rubin; Robert Wolkow; Delbert Robinson
Journal:  Am J Psychiatry       Date:  2002-01       Impact factor: 18.112

8.  Early childhood OCD: preliminary findings from a family-based cognitive-behavioral approach.

Authors:  Jennifer B Freeman; Abbe M Garcia; Lisa Coyne; Chelsea Ale; Amy Przeworski; Michael Himle; Scott Compton; Henrietta L Leonard
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-05       Impact factor: 8.829

9.  Treatment of depressive and obsessive-compulsive symptoms in OCD by imipramine and behaviour therapy.

Authors:  E B Foa; M J Kozak; G S Steketee; P R McCarthy
Journal:  Br J Clin Psychol       Date:  1992-09

10.  D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.

Authors:  Eric A Storch; Lisa J Merlo; Michael Bengtson; Tanya K Murphy; Mark H Lewis; Mark C Yang; Marni L Jacob; Michael Larson; Adam Hirsh; Melanie Fernandez; Gary R Geffken; Wayne K Goodman
Journal:  Int Clin Psychopharmacol       Date:  2007-07       Impact factor: 1.659

View more
  39 in total

1.  Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.

Authors:  Martin E Franklin; Jeffrey Sapyta; Jennifer B Freeman; Muniya Khanna; Scott Compton; Daniel Almirall; Phoebe Moore; Molly Choate-Summers; Abbe Garcia; Aubrey L Edson; Edna B Foa; John S March
Journal:  JAMA       Date:  2011-09-21       Impact factor: 56.272

2.  Can claims-based data be used to recruit black and Hispanic subjects into clinical trials?

Authors:  Ana M Palacio; Leonardo J Tamariz; Claudia Uribe; Hua Li; Ellen J Salkeld; Leslie Hazel-Fernandez; Olveen Carrasquillo
Journal:  Health Serv Res       Date:  2011-08-30       Impact factor: 3.402

3.  Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?

Authors:  Michael G Wheaton; David Rosenfield; Edna B Foa; H Blair Simpson
Journal:  J Consult Clin Psychol       Date:  2015-05-25

4.  Race/Ethnicity and Treatment Outcome in a Randomized Controlled Trial for Trichotillomania (Hair-Pulling Disorder).

Authors:  Martha J Falkenstein; Kate Rogers; Elizabeth J Malloy; David A F Haaga
Journal:  J Clin Psychol       Date:  2015-04-01

5.  The impact of symptom dimensions on outcome for exposure and ritual prevention therapy in obsessive-compulsive disorder.

Authors:  Monnica T Williams; Samantha G Farris; Eric N Turkheimer; Martin E Franklin; H Blair Simpson; Michael Liebowitz; Edna B Foa
Journal:  J Anxiety Disord       Date:  2014-06-14

6.  Recruitment of a hidden population: African Americans with obsessive-compulsive disorder.

Authors:  Monnica T Williams; Dante Proetto; Delane Casiano; Martin E Franklin
Journal:  Contemp Clin Trials       Date:  2011-09-29       Impact factor: 2.226

7.  Treatment of obsessive-compulsive disorder in a nationwide survey of office-based physician practice.

Authors:  Sapana R Patel; Jennifer L Humensky; Mark Olfson; Helen Blair Simpson; Robert Myers; Lisa B Dixon
Journal:  Psychiatr Serv       Date:  2014-05-01       Impact factor: 3.084

8.  Demographic and health-related correlates of obsessive-compulsive symptoms among African Americans.

Authors:  Monnica T Williams; Robert Joseph Taylor; Joseph A Himle; Linda M Chatters
Journal:  J Obsessive Compuls Relat Disord       Date:  2017-07-08       Impact factor: 1.677

9.  The impact of a community-based clinical trial educational intervention among underrepresented Chinese Americans.

Authors:  Grace X Ma; Yin Tan; Natasha C Blakeney; Brenda F Seals; Xiang S Ma; Shumenghui Zhai; Amy Liu; Yanfei Tai; Margo Michaels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-03       Impact factor: 4.254

10.  Illness perception, help-seeking attitudes, and knowledge related to obsessive-compulsive disorder across different ethnic groups: a community survey.

Authors:  Lorena Fernández de la Cruz; Sarah Kolvenbach; Pablo Vidal-Ribas; Amita Jassi; Marta Llorens; Natasha Patel; John Weinman; Stephani L Hatch; Dinesh Bhugra; David Mataix-Cols
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2015-10-24       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.